Direct-to-patient clinical trial company Medable (Palo Alto, California) has added MaryAnne Rizk to its executive team.
Rizk formerly worked at IQVIA as a senior vice president, digital R&D strategy. She is also an adjunct professor at the Steven Institute of Technology (Hoboken, New Jersey) and a managing partner at Rizk Management Consulting.
In August, Rizk was named a PharmaVoice 100 leader.
She is also a member of the Healthcare Businesswomen’s Association, Prix Galien Foundation Digital Advisory Board and Society for Clinical Research Sites (SCRS) Innovation Council.
The startup Medable has continued to grow rapidly during the pandemic, scoring another $78 million in funding to help it continue advancing clients’ digital and decentralized clinical trials.
In her role at Medable, Rizk will work to bolster the company’s strategic partnerships and innovation ecosystem.
She will also endeavor to improve clinical trial diversity, which has become an increasing focus of pharma companies in recent years.
“MaryAnne shares our passion to make clinical research more inclusive, enabling global remote access so anyone anywhere can benefit from the latest therapies,” said Dr. Michelle Longmire, CEO and co-founder of Medable, in a statement. “No one company can do this alone, and we look forward to building deep and long-lasting partnerships to improve and give voice to the patient experience.”
Filed Under: clinical trials, Drug Discovery
